Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)

Archive ouverte

Quinquenel, Anne | Aurran-Schleinitz, Thérèse | Clavert, Aline | Cymbalista, Florence | Dartigeas, Caroline | Davi, Frédéric | de Guibert, Sophie | Delmer, Alain | Dilhuydy, Marie‐sarah | Feugier, Pierre | Fornecker, Luc‐matthieu | Ghez, David | Guieze, Romain | Laribi, Kamel | Leblond, Véronique | Leprêtre, Stéphane | Letestu, Rémi | Lévy, Vincent | Nguyen-Khac, Florence | Michallet, Anne-Sophie | Tomowiak, Cécile | Tournilhac, Olivier | Ysebaert, Loic | Troussard, Xavier

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Abstract As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO‐CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.

Consulter en ligne

Suggestions

Du même auteur

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Archive ouverte | Letestu, Rémi | CCSD

International audience. Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2...

TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia

Archive ouverte | Lazarian, Grégory | CCSD

International audience

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Archive ouverte | Michallet, Anne-Sophie | CCSD

International audience. n previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing...

Chargement des enrichissements...